Why the latest earnings matter for Syndax Pharmaceuticals (SNDX)

Syndax Pharmaceuticals (SNDX) reported first quarter 2026 revenue of US$64.86 million compared with US$20.04 million a year earlier, with net loss narrowing to US$42.67 million and loss per share at US$0.48, down from US$0.98.

Alongside the stronger quarterly figures, Syndax Pharmaceuticals’ recent price action has been mixed, with a 7 day share price return of 7.67% and a 30 day share price return down 12.07%. However, the 1 year total shareholder return of 95.54% points to strong longer term momentum.

If you are weighing Syndax’s recent move against other opportunities in the sector, this is a good moment to see what else is shaping healthcare focused AI, starting with 34 healthcare AI stocks.

With the stock up 95.54% over the past year but trading below some estimated value indicators, the key question is whether Syndax is still undervalued or whether the market is already pricing in future growth.

Most Popular Narrative: 45.6% Undervalued

Compared with the last close at $21.49, the most followed narrative points to a fair value of $39.50, anchoring a substantial valuation gap for Syndax.

Fixed operating expense base, together with expanding product sales and cash flow contributions from both franchises, is positioned to drive significant operating leverage, boosting net margins and accelerating the pathway to profitability. Late stage pipeline advancements (including frontline trials, lifecycle management, and expansion into new indications like IPF for Niktimvo), coupled with strong clinical data and market leading positions in precision oncology, provide robust long term growth avenues aligned with surging demand for targeted therapies, supporting multi year earnings momentum.

Want to see what underpins this valuation gap? The narrative leans on rapid revenue expansion, a sharp swing in margins, and a future earnings profile that assumes premium pricing power.

Result: Fair Value of $39.50 (UNDERVALUED)

However, this hinges heavily on Revuforj and Niktimvo, so any clinical or regulatory setback, or slower than expected uptake, could quickly challenge that undervalued story.

Next Steps

With sentiment clearly focused on upside potential, it makes sense to move quickly and test the story against the numbers yourself. To see exactly what optimism is based on, review the 2 key rewards

Looking for more investment ideas?

If Syndax has caught your eye, do not stop here. Use this momentum to line up a few more potential ideas that fit your goals.

• Spot potential bargains early by scanning 49 high quality undervalued stocks, which combines quality fundamentals with attractive pricing.
• Prioritize resilience by reviewing 71 resilient stocks with low risk scores, designed to highlight companies with sturdier risk profiles.
• Hunt for underfollowed opportunities by checking screener containing 21 high quality undiscovered gems before the crowd pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.